Ping An Biomedical Co., Ltd.
Ping An Biomedical Co., Ltd. Fundamental Analysis
Ping An Biomedical Co., Ltd. (PASW) shows moderate financial fundamentals with a PE ratio of 0.00, profit margin of -1.47%, and ROE of 19.68%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 72.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze PASW's fundamental strength across five key dimensions:
Efficiency Score
WeakPASW struggles to generate sufficient returns from assets.
Valuation Score
ExcellentPASW trades at attractive valuation levels.
Growth Score
WeakPASW faces weak or negative growth trends.
Financial Health Score
ModeratePASW shows balanced financial health with some risks.
Profitability Score
WeakPASW struggles to sustain strong margins.
Key Financial Metrics
Is PASW Expensive or Cheap?
P/E Ratio
PASW trades at 0.00 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, PASW's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Ping An Biomedical Co., Ltd. at 0.00 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 15.95 times EBITDA. This signals the market has high growth expectations.
How Well Does PASW Make Money?
Net Profit Margin
For every $100 in sales, Ping An Biomedical Co., Ltd. keeps $-1.47 as profit after all expenses.
Operating Margin
Core operations generate -0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $19.68 in profit for every $100 of shareholder equity.
ROA
Ping An Biomedical Co., Ltd. generates $-2.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
PASW converts 82.73% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.00
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.00
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.21
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-1.50
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.84
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
-0.02
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How PASW Stacks Against Its Sector Peers
| Metric | PASW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.00 | 25.34 | Better (Cheaper) |
| ROE | 19.68% | 1285.00% | Weak |
| Net Margin | -1.47% | -43090.00% (disorted) | Weak |
| Debt/Equity | -1.50 | 0.79 | Strong (Low Leverage) |
| Current Ratio | 0.84 | 10.66 | Weak Liquidity |
| ROA | -2.26% | -1544572.00% (disorted) | Weak |
PASW outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ping An Biomedical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
EPS CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
FCF CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure